BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs 2022;14:2014296. [PMID: 35030985 DOI: 10.1080/19420862.2021.2014296] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 50.0] [Reference Citation Analysis]
Number Citing Articles
1 Mak S, Marszal A, Matscheko N, Rant U. Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab. mAbs 2023;15. [DOI: 10.1080/19420862.2022.2149053] [Reference Citation Analysis]
2 Yaghoobizadeh F, Ardakani MR, Ranjbar MM, Galehdari H, Khosravi M. Expression, purification, and study on the efficiency of a new potent recombinant scFv antibody against the SARS-CoV-2 spike RBD in E. coli BL21. Protein Expr Purif 2023;203:106210. [PMID: 36473692 DOI: 10.1016/j.pep.2022.106210] [Reference Citation Analysis]
3 Colombo S, Alonso A, Real R, Goswami R, Suarez MC, Ogueta S, Almeida M, Adhikary L, Malmierca MG, de Melo IS. Improvement of monoclonal antibody stability by modulating trace metal iron concentration in cell culture media: A case study. Process Biochemistry 2023;125:130-140. [DOI: 10.1016/j.procbio.2022.12.013] [Reference Citation Analysis]
4 Yu X, Li T, Shen Z, Jing H, Xie X, Zhou X, Shen Y, Yang Y. The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation. Int Immunopharmacol 2023;116:109704. [PMID: 36689847 DOI: 10.1016/j.intimp.2023.109704] [Reference Citation Analysis]
5 Kuhne F, Heinrich K, Winter M, Fichtl J, Hoffmann G, Zähringer F, Spitzauer K, Meier M, Khan TA, Bonnington L, Wagner K, Stracke JO, Reusch D, Wegele H, Mormann M, Bulau P. Identification of Hetero-aggregates in Antibody Co-formulations by Multi-dimensional Liquid Chromatography Coupled to Mass Spectrometry. Anal Chem 2023. [PMID: 36669833 DOI: 10.1021/acs.analchem.2c03099] [Reference Citation Analysis]
6 Liu L, Chen J. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0033] [Reference Citation Analysis]
7 Lee SM, Min S, Kwon HS, Bae G, Jung JH, Park HI, Lee SH, Lim CS, Ko BJ, Lee JC, Jung ST. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of Immunoglobulin G and simultaneous binding to CD55 and CD20.. [DOI: 10.21203/rs.3.rs-2474854/v1] [Reference Citation Analysis]
8 Lippold S, Hook M, Spick C, Knaupp A, Whang K, Ruperti F, Cadang L, Andersen N, Vogt A, Grote M, Reusch D, Haberger M, Yang F, Schlothauer T. CD3 Target Affinity Chromatography Mass Spectrometry as a New Tool for Function-Structure Characterization of T-Cell Engaging Bispecific Antibody Proteoforms and Product-Related Variants. Anal Chem 2023. [PMID: 36638115 DOI: 10.1021/acs.analchem.2c03827] [Reference Citation Analysis]
9 Fan S, Li W, Zhang K, Zou X, Shi W, Liu Z, Tang C, Huang W, Tang F. Enhanced antibody-defucosylation capability of α-L-fucosidase by proximity-based protein fusion. Biochem Biophys Res Commun 2023;645:40-6. [PMID: 36680935 DOI: 10.1016/j.bbrc.2023.01.031] [Reference Citation Analysis]
10 Schmitt J, Razvi A, Grapentin C. Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks. MAbs 2023;15:2169440. [PMID: 36705325 DOI: 10.1080/19420862.2023.2169440] [Reference Citation Analysis]
11 Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs 2023;15:2153410. [PMID: 36472472 DOI: 10.1080/19420862.2022.2153410] [Reference Citation Analysis]
12 Haraya K, Tachibana T. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs 2023;37:99-108. [PMID: 36449140 DOI: 10.1007/s40259-022-00566-2] [Reference Citation Analysis]
13 Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
14 Yano Y, Hamano N, Haruta K, Kobayashi T, Sato M, Kikkawa Y, Endo-Takahashi Y, Tada R, Suzuki R, Maruyama K, Nomizu M, Negishi Y. Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide. Pharmaceutics 2022;15. [PMID: 36678759 DOI: 10.3390/pharmaceutics15010130] [Reference Citation Analysis]
15 Tan KW, Ji P, Qian Z, Gao Q, Wang S, Li Q, Gu M, Zhang Q, Hou C, Huang Y, Lian D, Wang J, Zhang Z, Zhang S, Wu J, Zhou W. Rapidly accelerated development of neutralizing COVID-19 antibodies by reducing cell line and CMC development timelines. Biotechnol Bioeng 2022. [PMID: 36482495 DOI: 10.1002/bit.28302] [Reference Citation Analysis]
16 Moises JE, Regl C, Hinterholzer A, Huber CG, Schubert M. Unambiguous Identification of Glucose-Induced Glycation in mAbs and other Proteins by NMR Spectroscopy. Pharm Res 2022. [PMID: 36510116 DOI: 10.1007/s11095-022-03454-0] [Reference Citation Analysis]
17 Kończak J, Janusz B, Młokosiewicz J, Satława T, Wróbel S, Dudzic P, Krawczyk K. Structural pre-training improves physical accuracy of antibody structure prediction using deep learning.. [DOI: 10.1101/2022.12.06.519288] [Reference Citation Analysis]
18 Zhong X, D'Antona AM. A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production. Front Immunol 2022;13:1072702. [PMID: 36569848 DOI: 10.3389/fimmu.2022.1072702] [Reference Citation Analysis]
19 Tolcher AW. Antibody drug conjugates: The dos and don'ts in clinical development. Pharmacol Ther 2022;240:108235. [PMID: 35738430 DOI: 10.1016/j.pharmthera.2022.108235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Adedeji AO, Zhong F, Getz JA, Zhong Z, Halpern W. Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies. Toxicol Pathol 2022;50:910-9. [PMID: 36329562 DOI: 10.1177/01926233221131510] [Reference Citation Analysis]
21 Grace PS, Gunn BM, Lu LL. Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. Curr Opin Biotechnol 2022;78:102818. [PMID: 36242952 DOI: 10.1016/j.copbio.2022.102818] [Reference Citation Analysis]
22 Doyle K, Tsopanoglou A, Fejér A, Glennon B, del Val IJ. Automated assembly of hybrid dynamic models for CHO cell culture processes. Biochemical Engineering Journal 2022. [DOI: 10.1016/j.bej.2022.108763] [Reference Citation Analysis]
23 Furuhashi T, Weckwerth W. Isomer analysis by mass spectrometry in clinical science. TrAC Trends in Analytical Chemistry 2022. [DOI: 10.1016/j.trac.2022.116907] [Reference Citation Analysis]
24 Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Development of therapeutic antibodies for the treatment of diseases. Mol Biomed 2022;3:35. [PMID: 36418786 DOI: 10.1186/s43556-022-00100-4] [Reference Citation Analysis]
25 Tateyama N, Suzuki H, Ohishi T, Asano T, Tanaka T, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y. Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. Pharmaceutics 2022;14. [PMID: 36432687 DOI: 10.3390/pharmaceutics14112494] [Reference Citation Analysis]
26 Ausserwöger H, Schneider MM, Herling TW, Arosio P, Invernizzi G, Knowles TPJ, Lorenzen N. Non-specificity as the sticky problem in therapeutic antibody development. Nat Rev Chem 2022. [DOI: 10.1038/s41570-022-00438-x] [Reference Citation Analysis]
27 Ralston CY, Sharp JS. Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods. Antibodies (Basel) 2022;11. [PMID: 36412837 DOI: 10.3390/antib11040071] [Reference Citation Analysis]
28 Aguilar Rangel M, Bedwell A, Costanzi E, Taylor RJ, Russo R, Bernardes GJL, Ricagno S, Frydman J, Vendruscolo M, Sormanni P. Fragment-based computational design of antibodies targeting structured epitopes. Sci Adv 2022;8. [DOI: 10.1126/sciadv.abp9540] [Reference Citation Analysis]
29 Bousquet PA, Manna D, Sandvik JA, Arntzen MØ, Moreno E, Sandvig K, Krengel U. SILAC-based quantitative proteomics and microscopy analysis of cancer cells treated with the N-glycolyl GM3-specific anti-tumor antibody 14F7. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.994790] [Reference Citation Analysis]
30 Behrens LM, van Egmond M, van den Berg TK. Neutrophils as immune effector cells in antibody therapy in cancer. Immunological Reviews 2022. [DOI: 10.1111/imr.13159] [Reference Citation Analysis]
31 Olsen TH, Abanades B, Moal IH, Deane CM. KA-Search: Rapid and exhaustive sequence identity search of known antibodies.. [DOI: 10.1101/2022.11.01.513855] [Reference Citation Analysis]
32 Conner CM, van Fossan D, Read K, Cowley DO, Alvarez O, Xu S(, Webb DR, Jarnagin K. A HUMANIZED FCRN TRANSGENIC MOUSE FOR PRECLINICAL PHARMACOKINETICS STUDIES.. [DOI: 10.1101/2022.10.24.513622] [Reference Citation Analysis]
33 Meng J, Li R, Zhang Z, Wang J, Huang Q, Nie D, Fan K, Guo W, Zhao Z, Han Z. A Review of Potential Therapeutic Strategies for COVID-19. Viruses 2022;14. [PMID: 36366444 DOI: 10.3390/v14112346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Pasquiers B, Benamara S, Felices M, Nguyen L, Declèves X. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. IJMS 2022;23:12754. [DOI: 10.3390/ijms232112754] [Reference Citation Analysis]
35 Pei M, Wang Y, Tang L, Wu W, Wang C, Chen YL. Dual-target Bridging ELISA for Bispecific Antibodies. Bio Protoc 2022;12:e4522. [PMID: 36313202 DOI: 10.21769/BioProtoc.4522] [Reference Citation Analysis]
36 Pander G, Uhl P, Kühl N, Haberkorn U, Anderl J, Mier W. Antibody-drug conjugates: What drives their progress? Drug Discov Today 2022;27:103311. [PMID: 35787480 DOI: 10.1016/j.drudis.2022.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Qin Q, Liu H, He W, Guo Y, Zhang J, She J, Zheng F, Zhang S, Muyldermans S, Wen Y. Single Domain Antibody application in bacterial infection diagnosis and neutralization. Front Immunol 2022;13:1014377. [DOI: 10.3389/fimmu.2022.1014377] [Reference Citation Analysis]
38 Liu H, Wei P, Aviszus K, Zhang Q, Linderberger J, Yang J, Liu J, Chen Z, Waheed H, Reynoso L, Downey GP, Frankel SK, Kappler JW, Marrack P, Zhang G. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. IJMS 2022;23:11325. [DOI: 10.3390/ijms231911325] [Reference Citation Analysis]
39 Aguilar MF, Garay AS, Attallah C, Rodrigues DE, Oggero M. Changes in antibody binding and functionality after humanizing a murine scFv anti-IFN-α2: From in silico studies to experimental analysis. Mol Immunol 2022;151:193-203. [PMID: 36166900 DOI: 10.1016/j.molimm.2022.09.006] [Reference Citation Analysis]
40 Kato K, Mukawa Y, Uemura S, Okayama M, Kadota Z, Hosozawa C, Kumamoto S, Furuta S, Iwaoka M, Araki T, Yamaguchi H. A protein identification method for proteomics using amino acid composition analysis with IoT-based remote control. Anal Biochem 2022;657:114904. [PMID: 36152875 DOI: 10.1016/j.ab.2022.114904] [Reference Citation Analysis]
41 Furusawa A, Choyke PL, Kobayashi H. NIR-PIT: Will it become a standard cancer treatment? Front Oncol 2022;12:1008162. [DOI: 10.3389/fonc.2022.1008162] [Reference Citation Analysis]
42 Seo S, Kwak MW, Kang E, Kim C, Park E, Kang TH, Kim J. Accelerating Antibody Design with Active Learning.. [DOI: 10.1101/2022.09.12.507690] [Reference Citation Analysis]
43 Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, Chiang HL, Sun CP, Lee IJ, Li WS, Hsieh HP, Tao MH, Wu HC. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci 2022;29:68. [PMID: 36096815 DOI: 10.1186/s12929-022-00852-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 da Silva RGL, Fischer BB, Schaeffer PR, Novaes HMD. The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading. Science and Public Policy 2022. [DOI: 10.1093/scipol/scac047] [Reference Citation Analysis]
45 Rodrigues KF, Yong WTL, Bhuiyan MSA, Siddiquee S, Shah MD, Venmathi Maran BA. Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology 2022;11:1308. [DOI: 10.3390/biology11091308] [Reference Citation Analysis]
46 Soeda K, Arai K, Yamamoto T, Ofuji K, Fukuda M, Hashimoto D, Yamanaka Y. Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.09.027] [Reference Citation Analysis]
47 Dias da Silva W, De Andrade SA, Megale ÂAA, De Souza DA, Sant’anna OA, Magnoli FC, Guidolin FR, Godoi KS, Saladini LY, Spencer PJ, Portaro FCV. Antibodies as Snakebite Antivenoms: Past and Future. Toxins 2022;14:606. [DOI: 10.3390/toxins14090606] [Reference Citation Analysis]
48 Waibl F, Fernández-quintero ML, Wedl FS, Kettenberger H, Georges G, Liedl KR. Comparison of hydrophobicity scales for predicting biophysical properties of antibodies. Front Mol Biosci 2022;9:960194. [DOI: 10.3389/fmolb.2022.960194] [Reference Citation Analysis]
49 Pitiot A, Heuzé-vourc’h N, Sécher T. Alternative Routes of Administration for Therapeutic Antibodies—State of the Art. Antibodies 2022;11:56. [DOI: 10.3390/antib11030056] [Reference Citation Analysis]
50 Liu T, Li Y, Xu J, Guo Q, Zhu L, Fu T, Li J, Zhang D, Qian W, Zhou X, Guo H, Hou S. Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins. J Pharm Biomed Anal 2022;220:115018. [PMID: 36030755 DOI: 10.1016/j.jpba.2022.115018] [Reference Citation Analysis]
51 Aubrey N, Gouilleux-Gruart V, Dhommée C, Mariot J, Boursin F, Albrecht N, Bergua C, Croix C, Gilotin M, Haudebourg E, Horiot C, Matthias L, Mouline C, Lajoie L, Munos A, Ferry G, Viaud-Massuard MC, Thibault G, Velge-Roussel F. Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality. Antibodies (Basel) 2022;11:54. [PMID: 35997348 DOI: 10.3390/antib11030054] [Reference Citation Analysis]
52 Roel-touris J, Nadal M, Marcos E. Design of extended metal-binding β-sandwiches from de novo immunoglobulin domains.. [DOI: 10.1101/2022.08.03.502643] [Reference Citation Analysis]
53 Lu H, Jin Y, Yang H, Tao Z, Chen J, Chen S, Feng Y, Xin H, Lu X. A trimeric immunoglobin G-binding domain outperforms recombinant protein G and protein L as a ligand for fragment antigen-binding purification. Journal of Chromatography A 2022. [DOI: 10.1016/j.chroma.2022.463464] [Reference Citation Analysis]
54 Peng X, Zhao Z, Liu L, Bai L, Tong R, Yang H, Zhong L. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. DDDT 2022;Volume 16:2639-2657. [DOI: 10.2147/dddt.s373780] [Reference Citation Analysis]
55 Ma H, Zhang X, Zheng P, Dube PH, Zeng W, Chen S, Cheng Q, Yang Y, Wu Y, Zhou J, Hu X, Xiang Y, Zhang H, Chiu S, Jin T. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. Cell Res 2022. [PMID: 35906408 DOI: 10.1038/s41422-022-00700-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell 2022;185:2789-805. [PMID: 35868279 DOI: 10.1016/j.cell.2022.05.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Simpson AP, Roghanian A, Oldham RJ, Chan HTC, Penfold CA, Kim HJ, Inzhelevskaya T, Mockridge CI, Cox KL, Bogdanov YD, James S, Tutt AL, Rycroft D, Morley P, Dahal LN, Teige I, Frendeus B, Beers SA, Cragg MS. FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell Rep 2022;40:111099. [PMID: 35858562 DOI: 10.1016/j.celrep.2022.111099] [Reference Citation Analysis]
58 Wilman W, Wróbel S, Bielska W, Deszynski P, Dudzic P, Jaszczyszyn I, Kaniewski J, Młokosiewicz J, Rouyan A, Satława T, Kumar S, Greiff V, Krawczyk K. Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery. Brief Bioinform 2022:bbac267. [PMID: 35830864 DOI: 10.1093/bib/bbac267] [Reference Citation Analysis]
59 Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, Booth SG, Elliott I, Inzhelevskaya T, Mockridge I, Penfold CA, Wagner A, Glennie MJ, White AL, Essex JW, Pearson AR, Cragg MS, Tews I. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci Immunol 2022;7:eabm3723. [DOI: 10.1126/sciimmunol.abm3723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Guzzeloni V, Veschini L, Pedica F, Ferrero E, Ferrarini M. 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. Antibodies 2022;11:46. [DOI: 10.3390/antib11030046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis 2022:S1473-3099(22)00311-5. [PMID: 35803289 DOI: 10.1016/S1473-3099(22)00311-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
62 Lythgoe MP, Sullivan R. Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval. European Journal of Cancer 2022;169:103-5. [DOI: 10.1016/j.ejca.2022.03.030] [Reference Citation Analysis]
63 Lu L, Liu X, Zuo C, Zhou J, Zhu C, Zhang Z, Fillet M, Crommen J, Jiang Z, Wang Q. In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS. Analytica Chimica Acta 2022. [DOI: 10.1016/j.aca.2022.340199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Jin L. Differentiation and verification of monoclonal antibody therapeutics by integrating accurate mass analyses at intact, subunit and subdomain levels for forensic investigation. Forensic Chemistry 2022;30:100434. [DOI: 10.1016/j.forc.2022.100434] [Reference Citation Analysis]
65 Golay J, Andrea AE, Cattaneo I. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. Front Immunol 2022;13:929895. [DOI: 10.3389/fimmu.2022.929895] [Reference Citation Analysis]
66 Thongkum W, Thongheang K, Tayapiwatana C. The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. Curr Issues Mol Biol 2022;44:2842-55. [PMID: 35877419 DOI: 10.3390/cimb44070195] [Reference Citation Analysis]
67 Fu Y, Xiao W, Mao Y. Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers 2022;14:3094. [DOI: 10.3390/cancers14133094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lee JH, Kim JW, Yang HR, Song S, Lee S, Jeon Y, Ju A, Lee N, Kim M, Kim M, Hwang K, Yoon JH, Shim H, Lee S. A Fully-Human Antibody Specifically Targeting a Membrane-Bound Fragment of CADM1 Potentiates the T Cell-Mediated Death of Human Small-Cell Lung Cancer Cells. IJMS 2022;23:6895. [DOI: 10.3390/ijms23136895] [Reference Citation Analysis]
69 Tanemura H, Masuda K, Okumura T, Takagi E, Kajihara D, Kakihara H, Nonaka K, Ushioda R. Development of a stable antibody production system utilizing an Hspa5 promoter in CHO cells. Sci Rep 2022;12:7239. [PMID: 35610229 DOI: 10.1038/s41598-022-11342-1] [Reference Citation Analysis]
70 Rosace A, Bennett A, Oeller M, Mortensen MM, Sakhnini L, Sormanni P. Automated optimisation of solubility and conformational stability of antibodies and proteins.. [DOI: 10.1101/2022.05.20.492798] [Reference Citation Analysis]
71 Löhr T, Sormanni P, Vendruscolo M. Conformational Entropy as a Potential Liability of Computationally Designed Antibodies. Biomolecules 2022;12:718. [DOI: 10.3390/biom12050718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Palacios Y, Chavez-galan L. Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative? Pharmaceuticals 2022;15:616. [DOI: 10.3390/ph15050616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Custers M, Nestor L, De Bundel D, Van Eeckhaut A, Smolders I. Current Approaches to Monitor Macromolecules Directly from the Cerebral Interstitial Fluid. Pharmaceutics 2022;14:1051. [DOI: 10.3390/pharmaceutics14051051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Williams DM. The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma. J Manag Care Spec Pharm 2022;28:581-3. [PMID: 35471066 DOI: 10.18553/jmcp.2022.28.5.581] [Reference Citation Analysis]
75 Tscheuschner G, Kaiser MN, Lisec J, Beslic D, Muth T, Krüger M, Mages HW, Dorner BG, Knospe J, Schenk JA, Sellrie F, Weller MG. MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour. Antibodies 2022;11:27. [DOI: 10.3390/antib11020027] [Reference Citation Analysis]
76 Liu T, Xu J, Guo Q, Zhang D, Li J, Qian W, Guo H, Zhou X, Hou S. Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab. Front Chem 2022;10:826923. [DOI: 10.3389/fchem.2022.826923] [Reference Citation Analysis]
77 Park UB, Jeong TJ, Gu N, Lee HT, Heo Y. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy. Biochemical and Biophysical Research Communications 2022;599:31-7. [DOI: 10.1016/j.bbrc.2022.02.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Bollenbach L, Buske J, Mäder K, Garidel P. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80? Int J Pharm 2022;620:121706. [PMID: 35367584 DOI: 10.1016/j.ijpharm.2022.121706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
79 Schindler C, Faust C, Sjuts H, Lange C, Kühn J, Dittrich W, Leuschner WD, Schiebler W, Hofmann J, Rao E, Langer T. A multivalent antibody assembled from different building blocks using tag/catcher systems: a case study. Protein Eng Des Sel 2022;35:gzac014. [PMID: 36373216 DOI: 10.1093/protein/gzac014] [Reference Citation Analysis]
80 Nihira K. Non-clinical safety evaluations of next-generation therapeutic antibodies. Folia Pharmacol Jpn 2022;157:458-463. [DOI: 10.1254/fpj.22049] [Reference Citation Analysis]
81 Rashid MH. Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation. MAbs 2022;14:2111748. [PMID: 36018829 DOI: 10.1080/19420862.2022.2111748] [Reference Citation Analysis]
82 Xu J, Ou J, McHugh KP, Borys MC, Khetan A. Upstream cell culture process characterization and in-process control strategy development at pandemic speed. MAbs 2022;14:2060724. [PMID: 35380922 DOI: 10.1080/19420862.2022.2060724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Dannheim FM, Walsh SJ, Orozco CT, Hansen AH, Bargh JD, Jackson SE, Bond NJ, Parker JS, Carroll JS, Spring DR. All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading. Chem Sci . [DOI: 10.1039/d2sc02198f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Rangel MA, Bedwell A, Costanzi E, Taylor R, Russo R, Bernardes GJL, Ricagno S, Frydman J, Vendruscolo M, Sormanni P. Fragment-based computational design of antibodies targeting structured epitopes.. [DOI: 10.1101/2021.03.02.433360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]